Case-Based Review

Epithelial Ovarian Cancer: Evaluation, Staging, Surgery, and Stage I and II Disease Management


 

Edited by: Arthur T. Skarin, MD, FACP, FCCP

Ovarian cancer is the second most common gynecologic cancer among women in the United States. It is also the fifth leading cause of cancer mortality in women and the leading cause of death among women with gynecologic malignancies. The American Cancer Society statistics released in 2015 estimate that 21,290 new cases of ovarian cancer will occur during the year, with approximately 14,180 deaths. Globally, there were 238,719 new cases of ovarian cancer diagnosed in 2012, representing 3.6% of all cancers in women, and nearly 151,905 deaths. The highest incidence of ovarian cancer occurs in northern, central, and eastern Europe, followed by western Europe and North America, with the lowest incidence in parts of Africa and Asia. The majority of women presenting with ovarian cancer will present at an advanced stage, and the 5-year survival in this group is less than 30%.

To read the full article in PDF:

Click here

Recommended Reading

Short-term hormone replacement therapy upped ovarian cancer risk
MDedge Hematology and Oncology
Aggressive surgery doesn’t necessarily improve survival from advanced ovarian cancer
MDedge Hematology and Oncology
Bevacizumab-enhanced chemo ‘new standard’ in metastatic cervical cancer
MDedge Hematology and Oncology
Women with self-reported lower-limb lymphedema after treatment for gynecological cancers: are they more likely to self-report psychosocial symptoms and less likely to use services?
MDedge Hematology and Oncology
New 9-valent HPV vaccine shown to be as effective as quadrivalent vaccine
MDedge Hematology and Oncology
Uterine cancer low in myomectomy with power morcellation
MDedge Hematology and Oncology
Targeted treatments improving ovarian cancer outcomes
MDedge Hematology and Oncology
Bevacizumab fails to improve outcomes for metastatic uterine leiomyosarcoma
MDedge Hematology and Oncology
Oral bisphosphonates linked with lower risk of endometrial cancer
MDedge Hematology and Oncology
ACIP votes on incorporating 9-valent HPV vaccine into recommendations
MDedge Hematology and Oncology